• Company
  • Publications
  • News & Events
  • Contact
  • Company
  • Publications
  • News & Events
  • Contact
    • Press Releases

      Archive

      SoftBank Ventures Leads $10M Investment in AI-Driven Drug Discovery Company twoXAR

      March 19, 2018

      • English
      • 中文
      • 한국어
      • 日本語

      twoXAR Announces Formation of Business Advisory Board

      November 27, 2017

      MIT Startup Exchange Names twoXAR to STEX25

      June 28, 2017

      twoXAR Announces Preclinical Proof-of-Concept Data on Type 2 Diabetes Candidate

      June 19, 2017

      twoXAR Appoints Brian Moriarty as CFO and Jill Jene, PhD, as SVP, Business Development

      May 15, 2017

      twoXAR to Present Data from In Vivo Studies Investigating New Rheumatoid Arthritis Drug Candidates at IMMUNOLOGY 2017

      May 3, 2017

    • Blog

      twoXAR teams up with SoftBank Ventures, Andreessen Horowitz, and OS Fund to identify new treatments for patients

      Andrew A. Radin, twoXAR CEO

      March 19, 2018

      Traditionally, building a portfolio of drug programs requires hundreds of millions of dollars and takes many years in the biopharmaceutical industry. The convergence of available biomedical data, affordable cloud computing, and advances in algorithms is now enabling companies to build these drug portfolios for an order of magnitude less money and in a fraction of the time it traditionally takes. This is precisely what twoXAR is doing. Using our artificial intelligence-driven drug discovery platform, we aim to find new, more effective treatments to benefit patients across therapeutic areas.

       

      Today I am proud to share that we have assembled a group of high-quality global investors who will help us achieve this vision. Our Series A, which is led by SoftBank Ventures... read post here

      How Much Dirt is Too Much Dirt — Quality Metrics in Gene Expression Analysis​

      Aaron Daugherty, twoXAR Manager, Discovery Software

      December 13, 2017

      At twoXAR we bring together a lot of disparate data to rapidly identify disease treatments. It’s through these different data that we gain our predictive power. However, more data isn’t always better — not if the new data is of poor quality. In other words, quantity doesn’t trump quality, and that’s because of a common data science saying: bad data in = bad data out. Because of this, we check the quality of our input data at multiple levels; some of this is a manual process, but we automate as much as possible.

       

      In July’s post, (ML)²: Myths and Legends of Machine Learning, I touched on the messiness of real world data and mentioned quality control checks; here, I will expand on that with an example of one of the checks we use for gene expression data... read post here.

      twoXAR Announces Business Advisory Board

      Andrew A. Radin, twoXAR CEO

      November 27, 2017

      From Day 1, our vision at twoXAR has been to “improve health through computation”. We’ve taken many steps along this journey, such as collaborations with leading companies like Santen and breaking new ground in the path to more efficacious treatments in liver cancer. As we continue to build momentum and scale our aspirations to help as many patients as possible, we’re increasingly drawing upon the expertise of industry veterans to guide our strategic decision-making.

       

      Given this, I’m pleased to announce the formation of twoXAR’s Business Advisory Board and welcome Judy Lewent, Jonathan MacQuitty, and Howie Rosen as we move forward... read post here.

      (ML)²: Myths and Legends of Machine Learning

      Aaron Daugherty, twoXAR Senior Scientist
      Riley Parsons, twoXAR Bioinformatics Intern

      July 25, 2017

      Skepticism is (and should be) a vital part of any science; statistics and data science are no exception. Statistician George Box nicely summed it up when he said, “all models are wrong, but some are useful”. Box reminds us that statistical models are just that: models. A simplified representation of the real-world will always have shortcomings. But we shouldn’t forget the last bit of Box’s saying: “some [models] are useful”. Although challenging, carefully constructed statistical models can be extremely useful... read post here.

      How machines are able to help you find a parking spot, a great place to stay, and the next medication you might take​

      Riley Parsons, twoXAR Bioinformatics Intern

      June 23, 2017

      • Google Maps now predicts how difficult it will be to park near your destination based on the behavior of other users in the area.
      • Airbnb uses attributes of its users and available properties to generate personalized search results that lead to higher booking rates.
      • twoXAR is predicting new drug candidates outside of the wet lab using biomedical data.

      These three accomplishments are all possible today because of machine learning... read post here.

      Synergizing against breast cancer

      Aaron Daugherty, twoXAR Senior Scientist

      May 10, 2017

      I was about twelve when I found out my grandmother had breast cancer. My parents did a good job of shielding me from the worst of the details, but there is no way to avoid fear that comes from a loved one being diagnosed with cancer. As a kid, there wasn’t much I could do, but my grandmother loves to tell the story of me trying to comfort her by telling her I was going to do research to help cure her cancer. Little did I know at the time that treating cancer is not as simple as taking a pill once a day and that even identifying the right medicine is akin to finding a needle in a haystack.

       

      Over the next seventeen years, as I pursued undergraduate and graduate studies in biology and genetics, I filled in those knowledge gaps, but felt no closer to changing the status quo of breast cancer... read post here.

    • Read full blog at: medium.com/@twoXAR

      Read older blog posts at andrewradin.com

       

    • Events

      Archive

      Financial Times US Healthcare & Life Sciences Summit​

      New York, NY

      May 10, 2018

      twoXAR CEO, Andrew A. Radin, speaks on AI, Robotics, Blockchain and the Digital Transformation of Healthcare and Life Sciences​ panel with Ashish Atreja, John Baldoni, Eric Perakskis, & Tom Stanis.

      MIT 2018 Startup Showcase Silicon Valley: The New Machines of Industry

      Menlo Park, CA

      March 15, 2018

      twoXAR CEO, Andrew A. Radin, speaks on The New Machines of Industry - Buy, Build or Partner: Manufacturing, IoT & AI panel with Marianne Wu, & Sangbae Kim.

      Precision Medicine World Conference - Silicon Valley

      Mountain View, CA
      January 22-24, 2018

      twoXAR CEO, Andrew A. Radin, presents How AI is Helping Find Better Medicines.

      2017 MIT Startup Showcase Japan​

      Takeda Shonan Research Center, Japan

      October 18, 2017

      twoXAR Chief Marketing Officer, Andrew M. Radin, discusses artificial intelligence in drug discovery.

      AI in Healthcare Summit 2017

      San Francisco, CA

      June 26-27, 2017

      twoXAR CEO, Andrew A. Radin, speaks on Accelerating Drug Discovery and Research with AI panel with Abraham Heifets, Vijay Pande, & Marina Sirota.

      Immunology 2017

      Washington, DC

      May 12-16, 2017

      twoXAR Senior Scientist, Aaron Daugherty, presents An Integrative Bioinformatics Approach Identifies In Vivo Validated Drug Candidates with Novel Mechanisms of Action in Rheumatoid Arthritis poster.

       

    • Feature Articles

      Archive

      twoXAR Lands $10M to Ramp Up AI-Based Drug Discovery Work

      Xconomy

      March 19, 2018

      Bioinformatics startups twoXAR bags $10M in Series A

      MedCityNews

      March 19, 2018

      Gormley’s Take: Punching Back at Liver Cancer

      Wall Street Journal
      June 2, 2017

      Supercomputers Are Stocking Next Generation Drug Pipelines

      WIRED

      March 29, 2017

      twoXAR merges artificial intelligence, drug discovery and… clones?

      MedCityNews

      March 19, 2017

      Silicon Valley Computational Drug Startup Takes on Glaucoma

      IEEE Spectrum
      March 13, 2017

    • Andrew A. Radin, CEO - TEDMED 2016

    • Media Mentions

      Archive

      Preparing Emerging Biotechs For The Best Deals​

      Scrip Pharma Intelligence

      February 23, 2018

      Top Silicon Valley VC Andreessen Horowitz is investing $450 million into biotech​

      Business Insider

      December 14, 2017

      AI Hunts for New ALS Treatments​

      Scientific American

      August 10, 2017

       

      AI-powered drug discovery captures pharma interest

      Nature Biotechnology

      July 12, 2017

      Big pharma turns to AI to speed drug discovery, GSK signs deal​

      Reuters

      July 1, 2017

      Management Tracks

      BioCentury

      May 17, 2017

    • Webinars, Podcasts, & Videos

      Archive

      Webinar: Practical Application of Artificial Intelligence in Drug Discovery and Development

      ShareVault Life Sciences VaultSeries

      October 12, 2017

      twoXAR CEO, Andrew A. Radin, is joined by GSK's John Baldoni & Nimbus's Mark Ashwell.

      Video: Andrew A. Radin TEDMED Talk

      TEDMED

      December 1, 2016

      twoXAR CEO, Andrew A. Radin, presents What if new medications could be found in minutes instead of years?

      Podcast: Move Fast But Don’t Break Things (When It Comes to Computational Biology)

      a16z Podcast

      June 14, 2016

      twoXAR CEO, Andrew A. Radin, is joined by Jeff Kindler & Vijay Pande.

    © 2018 twoXAR, Incorporated | All Rights Reserved

      Home
      News
      Contact